Literature DB >> 9935196

Classic Kaposi's sarcoma as a second primary neoplasm.

J Iscovich1, P Boffetta, R Winkelmann, P Brennan.   

Abstract

Although the incidence of classic Kaposi's sarcoma (CKS) has been investigated, its occurrence following a primary neoplasm and its association with this first neoplasm need to be determined. We analyzed a series of 124 patients with a secondary CKS (8.4% of a total of 1485 incident cases) which occurred between 1961 and 1992 in the Jewish Israeli population. Data on first neoplasms and subsequent Kaposi's sarcoma were retrieved from the Israel Cancer Registry. Acquired-immune-deficiency-syndrome-related Kaposi's sarcomas were excluded from the case series. Four controls were randomly selected for each CKS case among all Cancer Registry cases free from a second neoplasm at the time of diagnosis of the CKS in the case, and matched on gender, year of birth and year of diagnosis of the first neoplasm. The average time lapse between first neoplasm and secondary CKS was 4.5 years, being shorter for prostate cancer and for hematopoietic malignancies. As compared with Israel-born Jews, the risk of a subsequent CKS was significantly increased in immigrants [odds ratio (OR) 3.0]; this risk was particularly high in immigrants from the former Soviet Union (OR 9.4) and Poland (OR 7.0). There was no clear trend with age at immigration; however, low age at immigration and a short length of stay in Israel endowed a higher risk of developing a secondary CKS, markedly among patients suffering from solid tumors as the first primary. There was an excess of secondary CKS following a non-Hodgkin's lymphoma (OR 5.3), a Hodgkin's lymphoma (OR 7.5), a leukemia (OR 5.3) or a breast cancer (OR 2.2). Cancer patients with a first primary in the lung, colon, stomach, larynx, liver, pancreas or kidney showed secondary CKS less frequently. Despite the lack of control of therapy for the first neoplasm, development of secondary CKS seems to be mediated by mechanisms similar to those for hematopoietic neoplasms and selected nonhematopoietic neoplasms, such as breast cancer. The trend toward increased risk after a short time lapse and the difference in risk among immigrants indicate that genetic susceptibility is part of the complex interplay between cellular proliferation and control systems.

Entities:  

Mesh:

Year:  1999        PMID: 9935196     DOI: 10.1002/(sici)1097-0215(19990118)80:2<178::aid-ijc3>3.0.co;2-l

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells.

Authors:  T S Hyun; C Subramanian; M A Cotter; R A Thomas; E S Robertson
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Kaposi Sarcoma Revealing a Myelodysplastic Syndrome.

Authors:  Wafa Jouini; Faten Rabhi; Faten Gargouri; Kahena Jaber; Abderaouf Dhaoui
Journal:  Indian J Dermatol       Date:  2022 Jan-Feb       Impact factor: 1.757

3.  Risk factors for classical Kaposi sarcoma in a population-based case-control study in Sicily.

Authors:  Lesley A Anderson; Carmela Lauria; Nino Romano; Elizabeth E Brown; Denise Whitby; Barry I Graubard; Yan Li; Angelo Messina; Lorenzo Gafà; Francesco Vitale; James J Goedert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

4.  Classic Kaposi's sarcoma - complete response to radiation therapy: a case report.

Authors:  Kennet Ramírez; José Zavala; David Morán; Diana Hernández; Alberto Jiménez
Journal:  J Med Case Rep       Date:  2016-11-10

5.  Epigenetic Landscape of Kaposi's Sarcoma-Associated Herpesvirus Genome in Classic Kaposi's Sarcoma Tissues.

Authors:  Rui Sun; Xiaohua Tan; Xing Wang; Xiaodong Wang; Lei Yang; Erle S Robertson; Ke Lan
Journal:  PLoS Pathog       Date:  2017-01-24       Impact factor: 6.823

6.  Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995-2002).

Authors:  V Ascoli; G Minelli; M Kanieff; R Crialesi; L Frova; S Conti
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

7.  Leiomyosarcoma as a second metachronous malignant neoplasm following colon adenocarcinoma. A case report and review of the literature.

Authors:  A Mavrodontidis; C Zalavras; A Skopelitou; V Karavasilis; E Briasoulis
Journal:  Sarcoma       Date:  2001

8.  Quadruple Multiple Primary Malignancies: Early Detection of Second Primary Malignancy by Esophagogastroduodenoscopy/Colonoscopy Is Crucial for Patients with Classic Kaposi's Sarcoma.

Authors:  Nobuyuki Maruyama; Yuko Okubo; Masato Umikawa; Akiko Matsuzaki; Akira Hokama; Fusahiro Hirano; Tessho Maruyama; Kazuhide Nishihara; Toshiyuki Nakasone; Shoko Makishi; Hiroyuki Nakamura; Naoki Yoshimi
Journal:  Diagnostics (Basel)       Date:  2020-04-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.